Dr.dennis Burton
Co-Chair
pharmaceutical
The Scripps Research University
France
Biography
Dr.Dennis is a faculty, advisory board member, professor in The Scripps unversity. Dr. Dennis obtained his Ph.D from Lund university in Biochemistry.Dr.Dennis professional experience is from 2015-2017 Chairman, Immunology and Microbial Science (IMS), The Scripps Research Institute 1991-2017 Professor, Immunology and Microbial Science (IMS), The Scripps Research Institute 2015-2015 Distinguished Lecturer, The American Association of Immunologists -2012 Professor (Joint Appointment), Molecular Biology, The Scripps Research Institute 1990-1991 Personal Chair, The University of Sheffield 1989-1991 Visiting Member, Research Institute of Scripps Clinic 1985-1991 Jenner Fellow, Lister Institute of Preventive Medicine 1987-1990 Senior Lecturer in Biochemistry, The University of Sheffield 1981-1987 Lecturer in Biochemistry, The University of Sheffield 1980-1981 Junior Research Fellow, Wolfson College, University of Oxford 1979-1981 Medical Research Council Training Fellowship, University of Oxford.His publication is mainly focused on his reasearch work on immunology and its dysfunction.
Research Interest
Dr. Dennis is foused on Antibodies and Infectious Disease. The perception of man as the easy victor over microbes has changed dramatically in the last two decades. Vaccination has offered protection against a number of viral pathogens, but it is increasingly recognized that the strategies used in the past will not be successful against all viruses. Mainly focused on developing rational vaccine strategies, particularly against HIV and particularly using an approach termed “Reverse Vaccinology 2.0”. In this approach, broadly neutralizing antibodies isolated from natural HIV infection are investigated in interaction with their sole viral target, the HIV Envelope, and the data used to guide immunogen design and immunization strategies. Immunogens are then evaluated in detail in animal models and the results used to iteratively improve immunogens as we move toward an HIV vaccine suitable to protect humans.
